ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR113

Analysis of 40-Year Prognosis of 1149 cases of IgA Nephropathy and Validation Study of Oxford Classification

Session Information

  • Mostly IgA Nephropathy
    November 07, 2019 | Location: Ballroom C, Walter E. Washington Convention Center
    Abstract Time: 05:30 PM - 05:42 PM

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Moriyama, Takahito, Tokyo Women's Medical University, Tokyo, Japan
  • Nitta, Kosaku, Tokyo Women's Medical University, Tokyo, Japan
Background

Half a century has passed since IgA nephropathy (IgAN) was firstly reported, however, very long term prognosis over 40 years has been unknown. In 2016, Oxford classification of IgAN was revised, and crescent formation was newly added. In this study, we showed 40 years prognosis of IgAN and validation study of Oxford classification in our cohort.

Methods

1,149 IgAN patients diagnosed in our institution since 1974 were analyzed. At first, 40 years prognosis of whole cohort was analyzed. Then, 872 patients observed over 1 years and diagnosed by renal biopsy with more than 8 glomeruli were divided into two groups with or without immunosuppressant and evaluated about the Oxford classification.

Results

Renal survival rate of whole cohort was 86.8% in 10 years, 72.2% in 20 years, 58.2% in 30 years, and 49.9% in 40 years. In whole Oxford analysis cohort (n=872), only T lesion was related with 20 years renal prognosis (81.9 in T0, 58.7 in T1, and 34.7% in T2, P<0.0001). In group without immunosuppressant (n=416), 20 years renal survival rate was significantly higher in S0 than S1 (75.7 vs. 65.0%, P=0.04), in T0 than T1 and 2 (77.4 vs. 59.1 vs. 18.0%, P<0.0001), in C0 than C1+2 (71.9 vs. 60.1%, P=0.023), but not significant in M and E. In group with immunosuppressant (n=456), it was significantly higher in only T0 than T1 and 2 (87.3 vs. 55.7 vs. 54.7%, P<0.0001). Interestingly, survival rate in C1 (80.8%) was increased similar to C0 (76.6%) by immunosuppressant, but C2 was still low (58.8%). Multivariate Cox regression analysis showed lower eGFR and higher amount of proteinuria in every cohorts and T lesion in whole Oxford analysis cohort were independent risk factors. After propensity score matching (n=266/group), renal survival rate in group with immunosuppressant was significantly higher than without immunosuppressant (78.4 vs. 68.1%, p=0.0099), and it was also significantly higher than in M0 (83.0 vs. 70.1%, p=0.0277), E1 (85.2 vs. 65.1%, p=0.0051), S1 (80.0 vs. 63.5%, p=0.0031), T0 (91.6 vs. 81.6, p=0.003), T2 (62.5 vs. 0.0%, p=0.035), and C1 (82.5 vs. 62.5%, p=0.014).

Conclusion

Half of IgAN patients progressed to end stage within 40 years, and Oxford classification was evaluated to suspect prognosis especially T lesion, and immunosuppressant improved its prognosis especially in M0, E1, S1, T0, T2 and C1.